Kevin McKernan

But it's good to have someone like him with a different perspective that's more cautious about this because that can be sobering for when you're alone in a field like this. There's another group in Germany that reproduced it as well, and they actually got it through peer review, Bridget Koenig's group, which I was shocked by that they managed to push it through.

But it's good to have someone like him with a different perspective that's more cautious about this because that can be sobering for when you're alone in a field like this. There's another group in Germany that reproduced it as well, and they actually got it through peer review, Bridget Koenig's group, which I was shocked by that they managed to push it through.

But they've reproduced the work, and there's a group in Canada that I'm working with that reproduced it and put out a preprint. They have the largest study. They did about 30 vials, and they found that in all of them, the PCR data in that study shows that it's probably below the 10-anagram limit for most of it.

But they've reproduced the work, and there's a group in Canada that I'm working with that reproduced it and put out a preprint. They have the largest study. They did about 30 vials, and they found that in all of them, the PCR data in that study shows that it's probably below the 10-anagram limit for most of it.

But they've reproduced the work, and there's a group in Canada that I'm working with that reproduced it and put out a preprint. They have the largest study. They did about 30 vials, and they found that in all of them, the PCR data in that study shows that it's probably below the 10-anagram limit for most of it.

But if you use a different tool to measure it, fluorometry, which is probably the right way to do it, you end up being 100-fold over. So what this has revealed is that the pharmaceutical industry is playing games with how they measure this stuff, and the regulators can't keep up. If you measure their own patents, they don't measure it with PCR, yet the regulators say, hey, give us the numbers.

But if you use a different tool to measure it, fluorometry, which is probably the right way to do it, you end up being 100-fold over. So what this has revealed is that the pharmaceutical industry is playing games with how they measure this stuff, and the regulators can't keep up. If you measure their own patents, they don't measure it with PCR, yet the regulators say, hey, give us the numbers.

But if you use a different tool to measure it, fluorometry, which is probably the right way to do it, you end up being 100-fold over. So what this has revealed is that the pharmaceutical industry is playing games with how they measure this stuff, and the regulators can't keep up. If you measure their own patents, they don't measure it with PCR, yet the regulators say, hey, give us the numbers.

What did you use? PCR. Okay, they look like they passed. The regulators don't read the patents. They'll be like, their own patents tell you not to accept that number. If you read it with a different instrument, you get 100 times more, and you have a problem because it's LNP-based. So, so from a peer review standpoint, we don't care about peer review in the field.

What did you use? PCR. Okay, they look like they passed. The regulators don't read the patents. They'll be like, their own patents tell you not to accept that number. If you read it with a different instrument, you get 100 times more, and you have a problem because it's LNP-based. So, so from a peer review standpoint, we don't care about peer review in the field.

What did you use? PCR. Okay, they look like they passed. The regulators don't read the patents. They'll be like, their own patents tell you not to accept that number. If you read it with a different instrument, you get 100 times more, and you have a problem because it's LNP-based. So, so from a peer review standpoint, we don't care about peer review in the field.

We care about replication and we want replication done from adversaries, people who like believe in this and people who don't like, uh, it's, it's, it's reassuring to me that, that Philip's doing, Philip took the vaccines, right? He's not, we're not eye to eye on this vaccine stuff. He has very different opinions on that and that's fine.

We care about replication and we want replication done from adversaries, people who like believe in this and people who don't like, uh, it's, it's, it's reassuring to me that, that Philip's doing, Philip took the vaccines, right? He's not, we're not eye to eye on this vaccine stuff. He has very different opinions on that and that's fine.

We care about replication and we want replication done from adversaries, people who like believe in this and people who don't like, uh, it's, it's, it's reassuring to me that, that Philip's doing, Philip took the vaccines, right? He's not, we're not eye to eye on this vaccine stuff. He has very different opinions on that and that's fine.

And it's, and when it, when it works in his hands, it's like Bitcoin. If your enemies make it work, it's good money. Right. Right. You want money that that's a consensus gravity. The Russians believe in gravity as much as we do. They can both make it work. So that's how science works is if you're if your enemies can run it, not that Phil's my enemy. He's a good guy.

And it's, and when it, when it works in his hands, it's like Bitcoin. If your enemies make it work, it's good money. Right. Right. You want money that that's a consensus gravity. The Russians believe in gravity as much as we do. They can both make it work. So that's how science works is if you're if your enemies can run it, not that Phil's my enemy. He's a good guy.

And it's, and when it, when it works in his hands, it's like Bitcoin. If your enemies make it work, it's good money. Right. Right. You want money that that's a consensus gravity. The Russians believe in gravity as much as we do. They can both make it work. So that's how science works is if you're if your enemies can run it, not that Phil's my enemy. He's a good guy.

But the point is you want people all around the world being able to reproduce this. And they can't be from the same sort of ideological cloth in order for you to really consider it.

But the point is you want people all around the world being able to reproduce this. And they can't be from the same sort of ideological cloth in order for you to really consider it.

But the point is you want people all around the world being able to reproduce this. And they can't be from the same sort of ideological cloth in order for you to really consider it.